Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Protein Interactions May Now Be Defined in a Quick and Efficient Manner

Scientists from the Stowers Institute for Medical Research say they have created a new way to quickly and efficiently define individual protein associations. Their study (“Topological scoring of protein interaction networks”), published in Nature Communication

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Scientists from the Stowers Institute for Medical Research say they have created a new way to quickly and efficiently define individual protein associations. Their study (“Topological scoring of protein interaction networks”), published in Nature Communications, shows how the topological scoring (TopS) algorithm, created by Stowers researchers, can, by combining data sets, identify proteins that come together, according to the team.

“It remains a significant challenge to define individual protein associations within networks where an individual protein can directly interact with other proteins and/or be part of large complexes, which contain functional modules. Here we demonstrate the topological scoring (TopS) algorithm for the analysis of quantitative proteomic datasets from affinity purifications,” they wrote.

“Data is analyzed in a parallel fashion where a prey protein is scored in an individual affinity purification by aggregating information from the entire dataset. Topological scores span a broad range of values indicating the enrichment of an individual protein in every bait protein purification. TopS is applied to interaction networks derived from human DNA repair proteins and yeast chromatin remodeling complexes. TopS highlights potential direct protein interactions and modules within complexes. TopS is a rapid method for the efficient and informative computational analysis of datasets, is complementary to existing analysis pipelines, and provides important insights into protein interaction networks.”

The approach is similar to looking at the activities and interactions of all the individuals in a community and then selecting out the most meaningful interactions, some which may be very rare. The researchers are looking for the biological equivalent of two individuals who may be the only two in the entire community that participate in an important interaction.

“It’s a form of big data analysis that we are applying to proteomics data to identify and understand protein interaction networks,” said Michael Washburn, PhD, director of the Stowers Proteomics Center. “It’s complementary to a lot of techniques already in use so it can be used to ask and answer new questions.”

Protein data sets can be challenging to examine for meaningful information because they are so large. “You have thousands of proteins to look at,” said Mihaela Sardiu, PhD, a senior research specialist at Stowers. Understanding how a wide variety of proteins come together to do something, like repair DNA, is a difficult problem. “We wanted to simplify the problem.”

That meant instead of taking an overall view of everything, they hunted for less common events. Researchers did this by looking for bait (proteins that are already known to be involved in processes of interest) and prey (proteins that could interact with bait proteins) to see how they interacted in human DNA repair and yeast chromatin remodeling complexes. Through TopS, data is analyzed in a parallel fashion, meaning that data from several biologically-related baits are considered at the same time.

A key attribute of TopS is the ability to evaluate the preference of a prey protein for a bait relative to other baits. “Instead of calculating a score by concentrating only information of a single bait, we now aggregate information from the entire data set,” explained Sardiu.

Washburn and Sardiu believe that TopS can be applied to a wide range of data sets beyond proteomics, in both basic research and beyond. Sardiu sees potential in using it for healthcare data, where physicians might be able to compare a patient’s health to others, like being able to tell if a patient’s disease is “really advanced compared to others or not,” she said.

The team has also published these findings on Github, a computer code repository, because they want to offer other researchers the opportunity to test the algorithm and see how they can apply it to their own projects.

“We’re excited to see how far this can go. It’s a potentially high impact tool and we want to see what other creative and innovative people can come up with,” said Washburn. “We think this is a really valuable potential tool for a lot of people out there who struggle with the challenge of sorting through very large-scale data.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →